Literature DB >> 17356926

A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium.

Sophie Quoilin1, Veronik Hutse, Hans Vandenberghe, Françoise Claeys, Els Verhaegen, Liesbet De Cock, Frank Van Loock, Geert Top, Pierre Van Damme, Robert Vranckx, Herman Van Oyen.   

Abstract

Ten years after the first seroprevalence study performed in Flanders, the aim of this cross sectional study was to follow the evolution of hepatitis A, B and C prevalence. The prevalence of hepatitis A antibodies, hepatitis B surface antigen and hepatitis C antibodies was measured in oral fluid samples collected by postal survey. Using the National Population Register, an incremental sampling plan was developed to obtain a representative sampling of the general population. A total of 24,000 persons were selected and 6,000 persons among them contacted in a first wave. With 1834 participants a response rate of 30.6% was achieved. The prevalence was weighted for age and was 20.2% (95% CI 19.43-21.08) for hepatitis A, 0.66% (95% CI 0.51-0.84) for hepatitis B surface antigen and 0.12% (95% CI 0.09-0.39) for hepatitis C. The prevalence of hepatitis A and C in the Flemish population is lower in 2003 compared with the results of the study performed in 1993. The difference may be due to a real decrease of the diseases but also to differences in the methodology. The prevalence of hepatitis B surface antigen remains stable. Considering the 30% response rate and the high quality of the self-collected samples as reflect of a good participation of the general population, saliva test for prevalence study is a good epidemiological monitoring tool.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356926     DOI: 10.1007/s10654-007-9105-6

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  27 in total

1.  Oral fluid collection by post--a pilot study of two approaches.

Authors:  M C Morris; W J Edmunds; E Miller; D W G Brown
Journal:  Public Health       Date:  2002-03       Impact factor: 2.427

2.  The prevalence of hepatitis C in England and Wales.

Authors:  M A Balogun; M E Ramsay; L M Hesketh; N Andrews; K P Osborne; N J Gay; P Morgan-Capner
Journal:  J Infect       Date:  2002-11       Impact factor: 6.072

3.  Detection of HCV antibodies in oral fluid.

Authors:  L De Cock; V Hutse; E Verhaegen; S Quoilin; H Vandenberghe; R Vranckx
Journal:  J Virol Methods       Date:  2004-12-15       Impact factor: 2.014

4.  Oral fluid as a medium for the detection of hepatitis B surface antigen.

Authors:  Veronik Hutse; Els Verhaegen; Liesbet De Cock; Sophie Quoilin; Hans Vandenberghe; Yves Horsmans; Peter Michielsen; Pierre Van Damme; Hans Van Vlierberghe; Françoise Claeys; Robert Vranckx; Herman Van Oyen
Journal:  J Med Virol       Date:  2005-09       Impact factor: 2.327

5.  Telephone reminders are a cost effective way to improve responses in postal health surveys.

Authors:  M Salim Silva; W T Smith; G Bammer
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

6.  High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the "cotton-filter" in transmission: the GEMT Study.

Authors:  B Denis; M Dedobbeleer; T Collet; J Petit; M Jamoulle; A Hayani; R Brenard
Journal:  Acta Gastroenterol Belg       Date:  2000 Apr-Jun       Impact factor: 1.316

7.  Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Anthony E Fiore; Annemarie Wasley; Beth P Bell
Journal:  MMWR Recomm Rep       Date:  2006-05-19

8.  [Fall in the seroprevalence of hepatitis A in French youth].

Authors:  M Joussemet; J Depaquit; E Nicand; C Mac Nab; J B Meynard; R Teyssou; G Fabre; Y Buisson
Journal:  Gastroenterol Clin Biol       Date:  1999-04

9.  Anti-hepatitis A in the general population and in hepatitis A vaccinees using saliva and serum as diagnostic media.

Authors:  W M Hurni; D Laufer; W J Miller; J Ryan; B Watson
Journal:  Ann N Y Acad Sci       Date:  1993-09-20       Impact factor: 5.691

10.  Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences.

Authors:  Mario Espinosa; Alejandro Martn-Malo; Raquel Ojeda; Rafael Santamara; Sagrario Soriano; Marisa Aguera; Pedro Aljama
Journal:  Am J Kidney Dis       Date:  2004-04       Impact factor: 8.860

View more
  16 in total

1.  Recent trends in publications in the European Journal of Epidemiology.

Authors:  Albert Hofman
Journal:  Eur J Epidemiol       Date:  2008       Impact factor: 8.082

2.  Evaluation of saliva specimens as an alternative sampling method to detect hepatitis B surface antigen.

Authors:  Helena Medina Cruz; Elisangela Ferreira da Silva; Cristiane A Villela-Nogueira; Letícia C Nabuco; Kycia Maria Rodrigues do Ó; Lia Laura Lewis-Ximenez; Clara Fumiko Tachibana Yoshida; Elisabeth Lampe; Livia Melo Villar
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

3.  Rapid Salivary IgG Antibody Screening for Hepatitis A.

Authors:  Swinburne A J Augustine; Tarsha N Eason; Kaneatra J Simmons; Shannon M Griffin; Clarissa L Curioso; Malini K D Ramudit; Elizabeth A Sams; Kevin H Oshima; Alfred Dufour; Timothy J Wade
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

Review 4.  Update on hepatitis B and C virus diagnosis.

Authors:  Livia Melo Villar; Helena Medina Cruz; Jakeline Ribeiro Barbosa; Cristianne Sousa Bezerra; Moyra Machado Portilho; Letícia de Paula Scalioni
Journal:  World J Virol       Date:  2015-11-12

Review 5.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

6.  Comparative hepatitis A seroepidemiology in 10 European countries.

Authors:  S Kurkela; R Pebody; G Kafatos; N Andrews; C Barbara; B Bruzzone; D Butur; S Caplinskas; I Davidkin; A Hatzakis; W Hellenbrand; L M Hesketh; A Nardone; V Nemecek; A Pistol; Z Sobotová; R Vranckx; C G Anastassopoulou
Journal:  Epidemiol Infect       Date:  2012-01-25       Impact factor: 4.434

7.  The prevalence of hepatitis C virus infection and its related risk factors among the rural population of fars province, southern iran.

Authors:  Mohammad Reza Fattahi; Alireza Safarpour; Masood Sepehrimanesh; Seyed Mohammad Kazem Hosseini Asl; Faezeh Mohamaddoust
Journal:  Hepat Mon       Date:  2015-02-06       Impact factor: 0.660

8.  Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation.

Authors:  H Theeten; V Hutse; K Hoppenbrouwers; P Beutels; P VAN Damme
Journal:  Epidemiol Infect       Date:  2013-05-21       Impact factor: 4.434

Review 9.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

Review 10.  Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review.

Authors:  S H I Hofstraat; A M Falla; E F Duffell; S J M Hahné; A J Amato-Gauci; I K Veldhuijzen; L Tavoschi
Journal:  Epidemiol Infect       Date:  2017-09-11       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.